The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of JT001
(VV116) for the early Treatment of Coronavirus Disease 2019 (COVID-19) in participants with
mild to moderate COVID-19, at high risk for progression to severe COVID-19, including death.